Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials, set to begin distribution in September 2025. This launch marks a significant milestone as the first complex generic in Glenmark’s portfolio in the institutional healthcare sector.
Glenmark’s Eribulin Mesylate Injection is bioequivalent and therapeutically equivalent to Eisai, Inc.’s Halaven® Injection, 1 mg/2 mL (0.5 mg/mL), a widely used treatment in oncology. According to IQVIA® sales data for the 12-month period ending July 2025, the Halaven® Injection market achieved annual sales of approximately $66.3 million, highlighting a strong demand for this therapy.
Marc Kikuchi, President & Business Head, North America, commented on the launch:
“We are pleased to announce the launch of Eribulin Mesylate Injection, 1 mg/2 mL Single-Dose Vials. As the first complex generic in our portfolio, this launch underscores our commitment to expanding our product offerings in the institutional channel and delivering high-quality, affordable alternatives for patients in need.”
Glenmark’s launch aims to provide hospitals and healthcare providers with a cost-effective alternative to the reference drug while maintaining the same therapeutic efficacy. The move reinforces Glenmark’s dedication to improving patient access to essential cancer therapies in the U.S. market.
